Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $472 million and $475 million for the...
Source: prnewswire.com
Page 4 - Prostate Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Prostate Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Prostate Score Today - Breaking & Trending Today
New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the...
Source: prnewswire.com
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX...
Source: prnewswire.com
Men with low health literacy less likely to choose active surveillance for prostate cancer after tumor profiling
April 9, 2021 Tumor gene profiling is a tool that can help patients with a cancer diagnosis make informed decisions about treatment. In predominantly white populations, among men with early stage, favorable-risk prostate cancer, these tools have been shown to increase patient acceptance of active surveillance — a common, evidence-based approach to monitor the tumor before a more aggressive treatment, like surgery or radiation. However, a new study from researchers at the University of Illinois Chicago and Northwestern University shows that in a predominantly Black, urban patient popu...
Source: uic.edu
Exact Sciences Announces Fourth Quarter 2020 Results
Exact Sciences Announces Fourth Quarter 2020 Results News provided by Share this article Share this article MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. "Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because of the pandemic," said Kevin Conroy, chairman and CEO of Exact Sciences. "We are a leader in cancer...
Source: prnewswire.com